The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation | Zendy

Andreas Straub | Zendy; HP Wendel | Zendy; Ricardo Bentes Azevedo | Zendy; Gerhard Ziemer | Zendy

Open Access

The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation

Author(s) -

Andreas Straub,

HP Wendel,

Ricardo Bentes Azevedo,

Gerhard Ziemer

Publication year - 2005

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1016/j.ejcts.2004.12.005

Subject(s) - abciximab , platelet , platelet activation , cardiopulmonary bypass , pharmacology , whole blood , p selectin , medicine , elastase , immunology , chemistry , myocardial infarction , biochemistry , enzyme , conventional pci

Cardiopulmonary bypass (CPB) induces a systemic inflammatory response and increases expression of the platelet activation marker P-selectin which mediates binding of platelets to leukocytes. Inhibition of the platelet GP IIb/IIIa receptor during CPB has been shown to protect platelets without increasing bleeding complications and is assumed to reduce the inflammatory response. The aim of this study was to investigate the effect of the GP IIb/IIIa inhibitor abciximab (ReoPro) on the function and interaction of platelets and leukocytes during experimental CPB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research